RGNT

Collaboration with leading European orthopedic center in Italy supports GelrinC® clinical adoptionRenowned cartilage regeneration expert Prof. Elizaveta Kon to help lead Regentis Centers of Excellence networkStrengthens surgeon engagement and expands Regentis' European commercialization infrastructureHERZLIYA, IL / ACCESS Newswire / April 16, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced a collaboration with Humanitas Research Hospital in Milan, Italy, one of Europe's leading academic medical centers in orthopedics and sports medicine. This collaboration is currently

3 - REGENTIS BIOMATERIALS LTD. (0001912966) (Issuer)

3 - REGENTIS BIOMATERIALS LTD. (0001912966) (Issuer)

3 - REGENTIS BIOMATERIALS LTD. (0001912966) (Issuer)

3 - REGENTIS BIOMATERIALS LTD. (0001912966) (Issuer)

3 - REGENTIS BIOMATERIALS LTD. (0001912966) (Issuer)

3 - REGENTIS BIOMATERIALS LTD. (0001912966) (Issuer)

3 - REGENTIS BIOMATERIALS LTD. (0001912966) (Issuer)

3 - REGENTIS BIOMATERIALS LTD. (0001912966) (Issuer)

3 - REGENTIS BIOMATERIALS LTD. (0001912966) (Issuer)

Breakthrough manufacturing process comes in preparation for upcoming commercial launch in Europe planned for later this yearProprietary process is already patented in several countries and is pending in the U.S.HERZLIYA, IL / ACCESS Newswire / March 17, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced it has developed a new manufacturing process for its lead product, GelrinC®, an off-the-shelf hydrogel synchronized erosion and resorbable implant for the treatment of painful injuries to focal articular knee cartilage. The proprietary new process does not require the use o

20-F/A - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)

20-F - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)

6-K - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)

$7.4 million in cash expected to provide runway to complete site expansion process and patient enrollment as part of pivotal Phase III FDA trial for GelrinCAlready approved in Europe, GelrinC is expected to be rolled out in clinics across the continent in 2026GelrinC is positioned to be the first ready-to-use, off-the-shelf product in the U.S. for knee cartilage repairHERZLIYA, IL / ACCESS Newswire / February 24, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company"), a regenerative medicine company focused on innovative tissue repair solutions, today reported financial results for the year ended December 31, 2025 and provided an update on corporate and clinical developments."2025 w

Dr. Reske has proven leadership in clinical development and regulatory affairs following key role in FDA approval of cartilage repair product Agili-C leading to CartiHeal's $330 million acquisitionHERZLIYA, ISRAEL / ACCESS Newswire / February 19, 2026 / Regentis Biomaterials Ltd., ("Regentis" or the "Company") (NYSE:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced the appointment of Dr. Galit Reske, PhD, as Chief Medical Officer (CMO). Dr. Reske brings extensive experience in clinical development, regulatory strategy, and global clinical operations across the United States, Europe, and Israel, with a particular focus on cartilage repair an

SCHEDULE 13G - REGENTIS BIOMATERIALS LTD. (0001912966) (Subject)

6-K - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)

With CE Mark approval, GelrinC is slated for commercial launch in Europe in 2026New clinical sites to support engagement with leading orthopedic surgeons and centers of excellence in key European markets, strengthening Regentis' positioning for commercial launch and broader clinical adoptionHERZLIYA, ISRAEL / ACCESS Newswire / February 17, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company"), a regenerative medicine company focused on innovative tissue repair solutions, today announced the expansion of its European clinical site network into new countries, strengthening its infrastructure to support both ongoing clinical programs including its pivotal Phase III U.S. Food and Drug

6-K - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)

GelrinC, the only restorative product for knee cartilage repair, has CE Mark approval in Europe and is currently at the midpoint of a pivotal FDA Phase III trial in the U.S.Ori Gon brings substantial public company, medtech, and capital markets experienceHERZLIYA, ISRAEL / ACCESS Newswire / February 4, 2026 / Regentis Biomaterials Ltd., ("Regentis" or the "Company") (NYSE:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced the appointment of Ori Gon as Chief Financial Officer and Chief Business Officer, effective immediately. Mr. Gon will lead the Company's commercial and business development activities, as well as its financial strategy, pla

6-K - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)

New sites expected to further accelerate patient enrollment, which surpassed 50% in Phase III study, as well as support future clinical programsGelrinC is set to transform cartilage repair market with off-the-shelf regenerative productsHERZLIYA, ISRAEL / ACCESS Newswire / January 29, 2026 / Regentis Biomaterials Ltd., ("Regentis" or the "Company") (NYSE:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced the expansion of its U.S. clinical site network, further strengthening its infrastructure to support its ongoing pivotal Phase III study of GelrinC® for knee cartilage repair as well as future clinical programs."Building on our existing clini

6-K - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)

2 years after treatment, GelrinC-treated patients demonstrated layered cartilage architecture similar to native hyaline cartilage - widely regarded as the gold standard for durable joint functionThis rare outcome in cartilage repair suggests true biological cartilage regeneration, not merely defect fillingUnlike traditional scaffolds, GelrinC limits fibrotic tissue overgrowth, supporting smoother joint motion and preserving natural biomechanicsHERZLIYA, IL / ACCESS Newswire / January 20, 2026 / Regentis Biomaterials Ltd., ("Regentis" or the "Company") (NYSE:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced new long-term imaging data from it